Endometrial Neoplasms clinical trials
The registry lists 1,425 studies for Endometrial Neoplasms across more than 10 countries. 473 are recruiting or about to start. 775 of them are mainly about Endometrial Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 2 narrower conditions too, such as Carcinoma, Endometrioid: 1,469 studies, 477 open.
ClinicalTrials.gov finds 1,664 studies for Endometrial Neoplasms. How that becomes 1,423 here
This page counts the studies the registry files under Endometrial Neoplasms, and those it files under no condition that list Endometrial Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 1,664Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −36Filed under a narrower condition, counted on its own pageCarcinoma, Endometrioid 14 · Sarcoma, Endometrial Stromal 9
- −16List Endometrial Neoplasms as a condition, but the registry did not file them under itMost often written as “Advanced Endometrial Carcinoma” (2), “Early Stage Endometrial Cancer” (1), and “Microsatellite Instability (MSI)-High Endometrial Cancer” (1). The registry filed them under other conditions only, most often Ovarian Neoplasms (5) and Recurrence (4).
- −191Match it another way86 name it in the title, 2 in a keyword, and 103 by a synonym or other text the search reads.
- 1,421Counted here and found by its search26 of them list Endometrial Neoplasms in their own words; the registry filed them under no condition.
- +2
Counted here, but its search does not find them
- 1,423The count on this page
Get an email when these change. Save the Endometrial Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (48) · M.D. Anderson Cancer Center (40) · Memorial Sloan Kettering Cancer Center (30) · Peking University People's Hospital (19) · Mayo Clinic (19) · Gynecologic Oncology Group (18) · UNC Lineberger Comprehensive Cancer Center (18) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (17)
What is being tested here
Drugs under test in Endometrial Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Dostarlimab | 11 | 3 | 17 |
| Paclitaxel | 7 | 5 | 38 |
| Pembrolizumab | 5 | 8 | 25 |
| Letrozole | 5 | 4 | 16 |
| Abemaciclib | 5 | 0 | 7 |
| Bevacizumab | 4 | 1 | 16 |
| Lenvatinib | 4 | 3 | 15 |
| Tirzepatide | 4 | 0 | 5 |
| Carboplatin | 3 | 3 | 25 |
| Olaparib | 3 | 3 | 11 |
Drug classes tested here Immune checkpoint inhibitors 42 open · Tyrosine kinase inhibitors (TKIs) 13 open · Antibody-drug conjugates (ADCs) 10 open · PARP inhibitors 9 open · Antimitotic agents 8 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) · Phase 3 · Merck Sharp & Dohme LLC
- Dec 2026Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions · Phase 3 · Peking Union Medical College Hospital
- Jan 2027Vaginal Cuff Brachytherapy Fractionation Study · Phase 3 · Kara Romano, MD
- May 2027Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) · Phase 3 · Merck Sharp & Dohme LLC
- Oct 2027Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) · Phase 3 · AstraZeneca
- Oct 2027Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · Phase 3 · National Cancer Institute (NCI)
- Nov 2026Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer · Memorial Sloan Kettering Cancer Center
- Nov 2026A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment · Harvard Medical School (HMS and HSDM)
- Nov 2026PROton Therapy for Post Surgical Treatment of GYNecologic Cancer · Abramson Cancer Center at Penn Medicine
- Nov 2026The Better, Harder, Faster, Stronger Study · Wake Forest University Health Sciences
Who these studies take
Of the 359 Endometrial Neoplasms studies recruiting now, 269 (75%) set no upper age limit and 54 (15%) stop at 75 or younger. 27 (8%) take children under 18. 222 (62%) are for women only and 0 (0%) for men only; 23 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 20 (6%) | 8 (2%) |
| 18 | 331 (92%) | 131 (36%) |
| 30 | 346 (96%) | 134 (37%) |
| 40 | 348 (97%) | 135 (38%) |
| 50 | 334 (93%) | 134 (37%) |
| 65 | 336 (94%) | 135 (38%) |
| 75 | 330 (92%) | 134 (37%) |
| 85 | 293 (82%) | 124 (35%) |
Across all 1,425 studies, recruiting or not: 12% stop at 75 or younger and 5% at 65; 11% take children; 69% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Endometrial Neoplasms studies take
Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 61 mo46–79 · 130 studies | 54 mo45–69 · 88 studies | 67 mo53–80 · 42 studies |
| Phase 1/2 | 69 mo54–106 · 79 studies | — | — |
| Phase 2 | 55 mo37–115 · 139 studies | — | 60 mo40–115 · 107 studies |
| Phase 3 | 53 mo45–126 · 44 studies | — | — |
| Interventional, no phase | 43 mo19–76 · 201 studies | — | 44 mo20–76 · 195 studies |
| Observational | 105 mo32–207 · 150 studies | — | 105 mo32–206 · 130 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting8
- Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial CancerNov 5, 2026NCT07867002
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerOct 30, 2026NCT07578649
- A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and FeasibilityOct 28, 2026NCT07675733
- A Phase I Study of XS-02 Capsules in Patients With Advanced Solid TumorsOct 26, 2026NCT06531486
- A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.Oct 26, 2026NCT07664735
Show 3 moreShow fewer
- Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or MetastaticOct 23, 2026NCT07807345
- A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsOct 19, 2026NCT07715747
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)Oct 15, 2026NCT07684599
Results posted3
- PRO1107 in Patients With Advanced Solid TumorsOct 29, 2026NCT06171789
- Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOct 21, 2026NCT04781088
- Single Agent ONC201 in Recurrent or Metastatic Endometrial CancerOct 14, 2026NCT03099499
Newly registered17
- Improving Rural Endometrial Cancer CareNov 10, 2026NCT07927244
- A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNov 10, 2026NCT07928258
- Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node Mapping in Patients With Endometrial CancerNov 4, 2026NCT07916610
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNov 2, 2026NCT07909031
- A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial CancerOct 28, 2026NCT07900256
Show 12 moreShow fewer
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersOct 28, 2026NCT07902375
- Remote Robotic Surgery for Gynecologic Cancer: A Safety and Effectiveness StudyOct 27, 2026NCT07896720
- Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic LymphadenectomyOct 26, 2026NCT07895212
- Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese PopulationsOct 23, 2026NCT07892755
- 27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer SurgeryOct 20, 2026NCT07882277
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsOct 20, 2026NCT07883798
- Protocol for Non-invasive Gynaecological Surveillance in Lynch SyndromeOct 16, 2026NCT07877779
- Effect of Weight Management on AMPK Activation in the Adjunctive Treatment of Endometrial CancerOct 16, 2026NCT07879365
- Cervical Cytology DNA Methylation for Endometrial Cancer ScreeningOct 15, 2026NCT07874529
- MTX-531-001 Phase 1 Study in Advanced Solid TumorsOct 15, 2026NCT07874880
- A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)Oct 13, 2026NCT07870278
- Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial CancerOct 13, 2026NCT07871838
Studies
Recruiting first, then most recently updated. Showing 50 of 1,425. Browse all 1,425 → or search them.
- A Study of LY4336619 in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07928258Phase 15 countries
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingNCT06952504Phase 334 countries
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsRecruitingNCT06515613Phase 12 countries
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerRecruitingNCT06340568Phase 327 countries
- Improving Rural Endometrial Cancer CareRecruitingNCT07927244Not applicable1 country
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesRecruitingNCT07503808Phase 13 countries
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingNCT07020221Phase 1/24 countries
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 21 country
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingNCT05112601Phase 21 country
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersRecruitingNCT07902375Not applicable1 country
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingNCT07198074Phase 31 country
- Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical CancerRecruitingNCT050517221 country
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsRecruitingNCT06586957Phase 12 countries
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingNCT06253494Phase 1/21 country
- Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial CancerRecruitingNCT07867002Phase 31 country
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsRecruitingNCT04165772Phase 21 country
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 17 countries
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruitingNCT053668811 country
- Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node Mapping in Patients With Endometrial CancerNot yet recruitingNCT07916610Not applicable
- Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic CancersNot yet recruitingNCT07815873Not applicable1 country
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/24 countries
- A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 17 countries
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Phase 211 countries
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsRecruitingNCT06695845Phase 24 countries
- Distance-Based Exercise to Preserve Function and Prevent DisabilityRecruitingNCT07059884Not applicable1 country
- A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)RecruitingNCT07684599Phase 33 countries
- A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)RecruitingNCT07286331Phase 310 countries
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerRecruitingNCT07166094Phase 319 countries
- Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsRecruitingNCT05856981Phase 13 countries
- Molecular and ctDNA Characterization of High-Risk Endometrial CancerRecruitingNCT070620161 country
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07909031Phase 1/21 country
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 22 countries
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRecruitingNCT07524322Phase 11 country
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsRecruitingNCT06305962Early Phase 11 country
- A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsRecruitingNCT07715747Phase 11 country
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsRecruitingNCT07262619Phase 1/215 countries
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerRecruitingNCT07578649Phase 35 countries
- HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial CancerRecruitingNCT07902999Phase 31 country
- Adaptive Radiotherapy for Safe HypofractionationNot yet recruitingNCT07516210Phase 21 country
- Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment DisorderRecruitingNCT07072728Phase 21 country
- A Phase 1 Study of LNCB74 in Advanced Solid TumorsRecruitingNCT06774963Phase 11 country
- Avera Cancer Sequencing and Analytics Protocol (ASAP)RecruitingNCT051420331 country
- A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial CancerNot yet recruitingNCT07900256Phase 2
- A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and FeasibilityRecruitingNCT07675733Not applicable1 country
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsRecruitingNCT07109726Phase 1/25 countries
- A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 13 countries
- A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid MalignanciesRecruitingNCT07197554Phase 11 country
- A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingRecruitingNCT07022483Phase 315 countries
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerRecruitingNCT05950464Phase 11 country
- Remote Robotic Surgery for Gynecologic Cancer: A Safety and Effectiveness StudyNot yet recruitingNCT07896720Not applicable